Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co Makes Case For Molnupiravir After Narrow FDA Nod

Backing Comes Day After Pfizer's Paxlovid Green Light

Executive Summary

US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."

You may also be interested in...



Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments

Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.

COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022

Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.

UK Nod For Pfizer’s COVID-19 Oral Treatment

Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel